Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological agents in the management of Felty's syndrome: a systematic review.
Narváez J, Domingo-Domenech E, Gómez-Vaquero C, López-Vives L, Estrada P, Aparicio M, Martín-Esteve I, Nolla JM. Narváez J, et al. Semin Arthritis Rheum. 2012 Apr;41(5):658-68. doi: 10.1016/j.semarthrit.2011.08.008. Epub 2011 Nov 25. Semin Arthritis Rheum. 2012. PMID: 22119104 Review.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles G, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano J, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Among authors: domingo domenech e. Blood Adv. 2024 May 28;8(10):2400-2404. doi: 10.1182/bloodadvances.2023011030. Blood Adv. 2024. PMID: 38531062 Free PMC article. No abstract available.
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R; Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH). Martínez C, et al. Ann Hematol. 2023 Feb;102(2):429-437. doi: 10.1007/s00277-022-05011-6. Epub 2022 Nov 12. Ann Hematol. 2023. PMID: 36370191 Free article.
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A; Spanish Group for the Study of CNS Disease in NHL. Quijano S, et al. J Clin Oncol. 2009 Mar 20;27(9):1462-9. doi: 10.1200/JCO.2008.17.7089. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224854
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas). González-Barca E, et al. Haematologica. 2007 Nov;92(11):1489-94. doi: 10.3324/haematol.11360. Haematologica. 2007. PMID: 18024397 Free article. Clinical Trial.
98 results